212 related articles for article (PubMed ID: 33294318)
1. Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey.
AlZahrani M; Clemons M; Vandermeer L; Sienkiewicz M; Awan AA; Hutton B; Pond GR; Ng TL
J Bone Oncol; 2021 Feb; 26():100339. PubMed ID: 33294318
[TBL] [Abstract][Full Text] [Related]
2. Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey.
Alzahrani M; Clemons M; Sienkiewicz M; Shrem NS; McGee SF; Vandermeer L; Sehdev S; Savard MF; Awan A; Canil C; Hutton B; Pond G; Saunders D; Ng T
Support Care Cancer; 2021 Nov; 29(11):6903-6912. PubMed ID: 34023950
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey.
McGee S; Alzahrani M; Vandermeer L; Cole K; Larocque G; Awan A; Hutton B; Pond G; Saunders D; Clemons M
Breast Cancer Res Treat; 2021 Jun; 187(2):477-486. PubMed ID: 33755864
[TBL] [Abstract][Full Text] [Related]
4. Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.
Alzahrani M; Stober C; Liu M; Awan A; Ng TL; Pond G; Alshamsan B; Vandermeer L; Clemons M
Support Care Cancer; 2022 May; 30(5):3977-3984. PubMed ID: 35059864
[TBL] [Abstract][Full Text] [Related]
5. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Anton A; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Semira MC; Gibbs P; Tran B; Pezaro C
Eur J Cancer; 2021 Nov; 157():485-492. PubMed ID: 34344533
[TBL] [Abstract][Full Text] [Related]
6. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
Mitchell AP; Mishra Meza A; Panageas KS; Lipitz-Snyderman A; Bach PB; Morris MJ
J Natl Cancer Inst; 2022 Mar; 114(3):419-426. PubMed ID: 34597380
[TBL] [Abstract][Full Text] [Related]
7. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
Clemons M; Ong M; Stober C; Ernst S; Booth C; Canil C; Mates M; Robinson A; Blanchette P; Joy AA; Hilton J; Aseyev O; Pond G; Jeong A; Hutton B; Mazzarello S; Vandermeer L; Kushnir I; Fergusson D;
Eur J Cancer; 2021 Jan; 142():132-140. PubMed ID: 33023785
[TBL] [Abstract][Full Text] [Related]
8. De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis.
Awan AA; Hutton B; Hilton J; Mazzarello S; Van Poznak C; Vandermeer L; Bota B; Stober C; Sienkiewicz M; Fergusson D; Shorr R; Clemons M
Breast Cancer Res Treat; 2019 Aug; 176(3):507-517. PubMed ID: 31079283
[TBL] [Abstract][Full Text] [Related]
9. Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.
Mitchell AP; Meza AM; Panageas KS; Lipitz-Snyderman A; Farooki A; Morris MJ
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):126-132. PubMed ID: 35798857
[TBL] [Abstract][Full Text] [Related]
10. Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer.
Clemons M; Liu M; Stober C; Pond G; Jemaan Alzahrani M; Ong M; Ernst S; Booth C; Mates M; Abraham Joy A; Aseyev O; Blanchette P; Vandermeer L; Tu M; Thavorn K; Fergusson D;
J Bone Oncol; 2021 Oct; 30():100388. PubMed ID: 34567960
[TBL] [Abstract][Full Text] [Related]
11. Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report.
Kaku T; Oh Y; Sato S; Koyanagi H; Hirai T; Yuasa M; Yoshii T; Nakagawa T; Miyake S; Okawa A
J Bone Oncol; 2020 Aug; 23():100301. PubMed ID: 32642421
[TBL] [Abstract][Full Text] [Related]
12. Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.
Mitchell AP; Persaud S; Palyca P; Salner A; Farooki A; Ostroff JS; Morris MJ; Chimonas S
Prostate; 2024 Feb; 84(2):177-184. PubMed ID: 37846041
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
[TBL] [Abstract][Full Text] [Related]
14. Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US.
McGrath LJ; Overman RA; Reams D; Cetin K; Liede A; Narod SA; Brookhart MA; Hernandez RK
Clin Epidemiol; 2018; 10():1349-1358. PubMed ID: 30288124
[TBL] [Abstract][Full Text] [Related]
15. De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.
Hutton B; Addison C; Mazzarello S; Joy AA; Bouganim N; Fergusson D; Clemons M
J Bone Oncol; 2013 Jun; 2(2):77-83. PubMed ID: 26909274
[TBL] [Abstract][Full Text] [Related]
16. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
Van Poznak C; Somerfield MR; Barlow WE; Biermann JS; Bosserman LD; Clemons MJ; Dhesy-Thind SK; Dillmon MS; Eisen A; Frank ES; Jagsi R; Jimenez R; Theriault RL; Vandenberg TA; Yee GC; Moy B
J Clin Oncol; 2017 Dec; 35(35):3978-3986. PubMed ID: 29035643
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer.
Tu MM; Clemons M; Stober C; Jeong A; Vandermeer L; Mates M; Blanchette P; Joy AA; Aseyev O; Pond G; Fergusson D; Ng TL; Thavorn K
Curr Oncol; 2021 May; 28(3):1847-1856. PubMed ID: 34068083
[TBL] [Abstract][Full Text] [Related]
18. Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review.
Ng TL; Tu MM; Ibrahim MFK; Basulaiman B; McGee SF; Srikanthan A; Fernandes R; Vandermeer L; Stober C; Sienkiewicz M; Jeong A; Saunders D; Awan AA; Hutton B; Clemons MJ
Support Care Cancer; 2021 Feb; 29(2):925-943. PubMed ID: 32535678
[TBL] [Abstract][Full Text] [Related]
19. Review of Bone Modifying Agents in Metastatic Breast Cancer.
Raghu Subramanian C; Talluri S; Mullangi S; Lekkala MR; Moftakhar B
Cureus; 2021 Feb; 13(2):e13332. PubMed ID: 33738175
[TBL] [Abstract][Full Text] [Related]
20. Uptake of bone-modifying agents in patients with HER2+ metastatic breast cancer with bone metastases - prospective data from a multi-site Australian registry.
Wong V; de Boer R; Dunn C; Anton A; Malik L; Greenberg S; Yeo B; Nott L; Collins IM; Torres J; Barnett F; Nottage M; Gibbs P; Lok SW
Intern Med J; 2022 Oct; 52(10):1707-1716. PubMed ID: 34002929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
